To systematically evaluate the efficacy and safety of ustekinumab compared with other second-line drugs for Crohn's disease(CD).
A systematic search of PubMed, Embase, Cochrane Library, and other databases for cohort studies comparing ustekinumab with other second-line therapies for the treatment of CD. Meta-analysis was performed by Review Manager 5.4 software.
A total of 10 literature studies were included, 1 222 patients in ustekinumab group and 949 patients in other drug groups. The results showed that the clinical remission rate[OR=1.75, 95%CI: (1.38, 2.21), P<0.001], steroid-free clinical remission rate[OR=1.54, 95%CI: (1.17, 2.01),P=0.002] and clinical response rate[OR=2.69, 95%CI: (1.10, 6.58), P=0.030] in ustekinumab group were higher than those of the other drug groups. In addition, the incidence of adverse events[OR=0.29, 95%CI: (0.09, 0.96), P=0.040]and discontinuation rate[OR=0.28, 95%CI: (0.17, 0.46), P<0.001] in ustekinumab group were lower than those of the other drug groups.
Ustekinumab is more effective and safer than the other second-line drugs for CD.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |